EU competition report could damage pharma sector, says EFPIA
This article was originally published in Scrip
Executive Summary
The EU competition authorities need to take a more balanced view of the challenges facing the pharmaceutical sector, otherwise they run the risk of damaging the innovative industry and undermining its efforts to deliver tangible public health benefits.